The Evolution of Breast Implants

2002 ◽  
Vol 10 (5) ◽  
pp. 223-236 ◽  
Author(s):  
Walter Peters

The present review traces the evolution of breast implants over the past 50 years. During the early years (from 1951 to 1962), a number of different sponges were used for breast augmentation. The first of these was Ivalon, a polyvinyl alcohol sponge. Other sponges were introduced subsequently, including Etheron (a poly-ether sponge popularized by Dr Paule Regnault in Montreal) and Polystan (fabric tapes that were wound into a ball). Subsequently, polyethylene strips enclosed in a fabric or polyethylene casing were also used for breast augmentation. All of these materials had similar outcomes. Although the initial results were encouraging, within one year of augmentation, breasts became very firm and lost over 25% of their volume. This was due to capsular contracture, a process that would lead to the collapse of the sponge and would continue to plague plastic surgeons and their patients for the next 50 years. In 1963, Cronin and Gerow introduced the silicone gel ‘natural feel’ implant, which revolutionized breast augmentation surgery. Approximately 10 companies have manufactured many types of silicone gel breast implants over the years. They obtained their raw materials for gels and shells from a similar number of other companies that entered and left the market at intervals. Many of the suppliers and manufactures changed their names and ownership over the years, and most of the companies no longer exist. No formal process of United States Food and Drug Administration premarket testing was in effect until 1988. There have been three generations of gel implants and a number of other lesser variations. First-generation implants (1963 to 1972) had a thick gel and a thick wall. They have generally remained intact over the years. Second-generation implants (1973 to the mid-1980s) had a thin gel and a thin wall. They have tended to disrupt over time. Third-generation implants (mid-1980s to 1992) had a thick wall and a thick gel. Except for those made by Surgitek, these implants remain intact. The breast implant business was competitive and companies introduced changes such as softer gels; barrier low-bleed shells; greater or lesser shell thickness; surface texturing; different sizes, contours and shapes; and multiple lumens in search of better aesthetics. Ultimately, more than 240 styles and 8300 models of silicone gel breast implants were manufactured in the United States alone. Inflatable breast implants were introduced in Toulons, France in 1965 (the Simaplast implant). There have been three main eras of inflatable implants: seamed, high-temperature vulcanized and room temperature vulcanized implants. In 1973, spontaneous deflation rates of 76% to 88% over three years were reported for many types of inflatable implants. Because of this, most plastic surgeons abandoned their use. From 1963 until the moratorium on gel implants (January 6, 1992), about 95% of all breast implants inserted were silicone gel filled. Only 5% were saline filled. Since the moratorium, this ratio has been reversed and 95% of all implants have been saline-filled, with only 5% being gel filled. Polyurethane-coated (PU) silicone gel implants were introduced in 1968. Over the next 20 years, they were shown to reduce the prevalence of capsular contracture to 2% to 3%. Other forms of surface texturing (Biocell, Siltex, multistructured implant) also appear to reduce capsular contracture with gel implants, but the reduction has been much less dramatic than that seen with PU implants. Contoured (anatomical) shaping appears to have advantages in some patients with gel implants. No such advantage has been seen for texturing or shaping with saline-filled implants. The story of gel implants has culminated in the largest class action lawsuit in medical history, with US$4.2 billion being awarded to women with silicone gel implants. During the past decade, there has been a tremendous amount of research on the reaction of a woman's body to gel implants. A plethora of studies have demonstrated that silicone gel implants are not associated with the development of any medical diseases. Silicone gel-filled implants have therefore been approved for use under Health Canada's Special Access Program. Silicone gel-filled implants may now be used in certain patients in whom they would provide advantages over saline implants. Silicone gel implants have not been approved for unrestricted general use. The evolution of breast implants occupies the past half century. It has been a stormy course, with many exciting advances and many bitter disappointments. The universe of breast implants is large and the variation among the implants is substantial. The purpose of the present review is to trace the evolution of breast implants over the past 50 years.

2019 ◽  
Vol 40 (5) ◽  
pp. 499-512 ◽  
Author(s):  
Frank Lista ◽  
Ryan E Austin ◽  
Maryam Saheb-Al-Zamani ◽  
Jamil Ahmad

Abstract Background Previous studies have reported decreased rates of capsular contracture associated with the use of textured surface breast implants placed in the subglandular plane during breast augmentation. However, since the publication of these studies, our understanding of the pathophysiology of capsular contracture, as well as the surgical techniques utilized to minimize bacterial contamination of the implant, have advanced considerably. Objectives The purpose of this study was to re-evaluate the relation between implant surface texturization and capsular contracture rates for breast implants placed in the subglandular plane during primary breast augmentation. Methods Retrospective chart review was performed of all primary subglandular breast augmentation procedures involving the use of either smooth or textured round silicone gel implants, with or without simultaneous mastopexy. The primary outcome measures included clinically significant capsular contracture (Baker grade III/IV) and revision surgery for capsular contracture. Results Between 2010 and 2017, 526 patients underwent primary subglandular breast augmentation with either smooth (n = 212) or textured (n = 314) round silicone gel implants; 248 patients underwent breast augmentation, whereas 278 underwent breast augmentation-mastopexy. Average follow-up was 756 days in the textured group and 461 days in the smooth group. Five cases of capsular contracture were observed in the textured group, and 7 cases of capsular contracture were observed in the smooth group (P = 0.20). Conclusions Smooth surface implants placed in the subglandular plane were not at a significantly increased risk of capsular contracture compared with textured surface implants. We suggest that adherence to a surgical technique focused on minimizing bacterial contamination of the implant is of greater clinical significance than implant surface characteristics when discussing capsular contracture. Level of Evidence: 4


2019 ◽  
Vol 1 (3) ◽  
Author(s):  
Maurizio Saturno ◽  
Sharon Stewart ◽  
Erin Bell ◽  
Emanuela Esposito

Abstract Background Silicone breast implants have been widely used for breast augmentation and reconstruction. During this time, silicone breast implants have undergone several modifications to improve their safety, quality, and clinical performance. Complications such as reoperation, capsular contracture, and rupture are risks often associated with breast implants. Objectives The authors conducted a retrospective study to analyze and report complication rates associated with Eurosilicone’s (Eurosilicone S.A.S, Apt, Cedex, France) silicone gel–filled breast implants over a period of 5 years. Methods In this retrospective clinical study, 2151 women who underwent either breast augmentation or breast reconstruction with Eurosilicone breast implants were diagnosed. Data on early and late complications including implant removal (explantation/exchange), capsular contracture, and rupture were collected using questionnaires, completed by 39 surgeons across Italy. Results Of the 2151, only 60 patients (2.78%) required implant removal. Twenty-five patients experienced capsular contracture (Baker Grade III/IV), giving an actual rate of 1.2%. The actual rate of implant rupture confirmed by breast magnetic resonance images was 0.18% (4 implants). Six patients (0.27%) were diagnosed with breast cancer following breast augmentation, and local complications including hematoma (1 patient) and seroma (2 patients) were experienced. Conclusions This retrospective clinical study involving Eurosilicone’s round and anatomical textured silicone gel–filled mammary implants demonstrates an excellent safety profile through 5 years. Level of Evidence: 2


1996 ◽  
Vol 4 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Walter Peters ◽  
Dennis Smith ◽  
Stanley Lugowski

There have been three generations of silicone-gel breast implants. First generation implants (thick wall – thick gel with Dacron patches) were made from 1963 to 1972. Second generation implants (thin wall-thin gel) were made from 1972 until the mid 1980s. The introduction of third generation implants (stronger wall, low-bleed) was geographically dependent. In Canada, Dow Corning Silastic II implants were introduced in 1986, and Surgitek SCL implants were introduced in 1988. In the present study, a total of 352 silicone-gel breast implants were removed from 239 patients between 1981 and 1995. Their failure properties were dependent upon their generation (year of manufacture) and, for second generation implants, their duration in situ. Of the 352 implants, 20 were first generation, and all were fully intact. Twenty-eight were third generation implants, and 27 were fully intact. Failure properties of the 302 second generation implants were dependent upon their duration of implantation. A survival curve indicated that these implants began to fail (by leaking or rupturing) after four years in situ. By six years, 40% had failed. After 12 years, 95% had failed. Of the 171 second generation implants removed between 1991 and 1995, 77% had failed. The failure properties were similar for the three main manufacturers: Dow Corning, Heyer-Schulte and Surgitek. The failure rate for second generation implants is much higher than was previously believed. This is particularly significant in view of the current difficulty in diagnosing implant failure.


1997 ◽  
Vol 5 (4) ◽  
pp. 241-245 ◽  
Author(s):  
Walter Peters

From 1992 to 1996, 189 saline breast implants were inserted into patients (54 for breast augmentation and 135 for replacement of explanted silicone gel implants). Nine implants (4.8%) underwent spontaneous deflation at a mean of 2.8 months postoperation (range, 0.5 to nine months). Six deflations were partial (10% to 50% of implant volume), and three were complete. All failed implants were from the same manufacturer and had the same leaf valves. None of the failed implants demonstrated any visible defects in their walls or valve mechanisms when examined in the operating room. However, subsequent analyses indicated that all failed implants demonstrated a slow leak through the leaf valve mechanism – as slow as two to three drops per 12 h. This rate increased significantly when pressure was applied to the implant. In the three implants with delayed leakage (six to 10 months), fibrous tissue was observed in the leaf valve mechanism of the implants. It is postulated that failure of all nine implants resulted because of defects in their valves and that fibrous tissue ingrowth into the leaf catheter valve mechanism may have played a role in at least three. The tissue may have provided a ‘wick’ to stimulate fluid leakage. The use of these leaf valve implants was discontinued one year ago. Since then, no failures have been observed in any of the 68 diaphragm valve implants that have been inserted during the past year.


2021 ◽  
Vol 14 (2) ◽  
pp. 140-146
Author(s):  
Viktoriia Dzhuganova ◽  
Valery V. NOVOMLINSKY ◽  
Andrey Petrovich Sokolov ◽  
Pavel Alekseevich Lynov ◽  
Margarita Gennedievna Sokolova ◽  
...  

Introduction. Fibroadenomas (FA) are the most common benign breast neoplasms that are diagnosed in 25% of women. Dissatisfaction with the size of the breast and the desire to increase it occurs in 40%. For this reason, in the practice of a plastic surgeon, there are cases when the patient wants to remove fibroadenomas (FA) and increase the size of the breast. In this situation, there are two options for managing the patient- the simultaneous execution of two operations and the delayed one.Aim. To evaluate the possibility of simultaneous FA removal and augmentation mammoplasty, to analyze possible complications and methods of their correction.Materials and methods. We have analyzed the experience of simultaneous interventions of FA removal and augmentation mammoplasty on the example of 10 cases performed in the period from 2014-2019, as well as FA removal after implant placement-3 cases.Results. Performing a simultaneous operation has advantages due to the minimization of injuries (the ability to perform from a single access - submammary or periareolar), reducing psychological stress and better cosmetic effect. Two patients had postoperative complications in the form of capsular contracture, manifested in the asymmetry of the mammary glands, corrected by performing capsulotomy and forming a new submammary fold. When performing invasive diagnostic tests and surgical intervention in three patients after endoprosthesis augmentation mammoplasty, extreme caution was required due to the risk of violating the integrity of the implant. It was found that the incision of the posterior leaf of the MJ capsule with a large number of removed neoplasms in the postoperative period leads to the development of breast asymmetry. The fact of FA recurrence was also confirmed (2 patients), who subsequently underwent repeated surgical intervention.Conclusion. Performing simultaneous operations for benign breast tumors can be surely practiced by plastic surgeons, including as one of the options for simultaneous treatment of breast FA and augmentation mammoplasty. The occurrence of FA in the long-term period after breast augmentation surgery is associated with difficulties in diagnostics (mammography and fine needle aspiration biopsy under the control of ultrasound), as well as in the course of surgery itself, due to the presence of the implant and the risk of violation of its integrity.


2019 ◽  
Vol 1 (2) ◽  
Author(s):  
Franck Duteille ◽  
Pierre Perrot ◽  
Marie-Hélène Bacheley ◽  
Erin Bell ◽  
Sharon Stewart

Abstract Background Although silicone breast implants have been available for over 60 years, their safety and efficacy continue to be assessed via long-term clinical and vigilance studies. Complications often associated with breast implant surgery include but are not limited to capsular contracture and rupture. Objective The authors investigate and evaluate the safety and performance of Eurosilicone’s (Eurosilicone S.A.S, Apt Cedex, France) Cristalline Paragel breast implants at least 10 years postimplantation. Methods Nine hundred and ninety-five of Eurosilicone’s textured mammary implants were implanted in 526 women undergoing primary (423 patients) and revision surgery (103 patients) at 17 centers throughout France. Complications were recorded at 3 months and annually thereafter for 10 years. Descriptive statistics were used and the Kaplan-Meier method was utilized to analyze key complications. Results Seventy-four women (98 implants) experienced capsular contracture across all cohorts. The Kaplan-Meier 10-year cumulative risk of capsular contracture (Baker Grade III/IV) per implant was 11.5% in the primary augmentation cohort and 25.2% in the primary reconstruction cohort. Sixteen implant ruptures were observed by surgeon examination giving a Kaplan-Meier risk of 3.8% per patient and 3.5% per implant. Surgical re-intervention (explantation/exchange) was reported 80 times resulting in a Kaplan-Meier cumulative risk of 13.3% and 31.6% for primary augmentation and primary reconstruction, respectively, per patient. Local complication rates including infection and seroma were low with risk rates of 0.6% and 0.2% by subject. Conclusions This multicenter clinical study demonstrates the long-term safety and efficacy profile through 10 years for Eurosilicone round and anatomical silicone gel breast implants. Level of Evidence: 3


Author(s):  
William B. Greene ◽  
Lyle G. Walsh ◽  
Richard M. Silver ◽  
Joann Allen ◽  
John C. Maize

Electron probe microanalysis of biopsies from two patients who had received silicone gel breast implants has revealed silicon (Si) in macrophages in an arthritic finger joint synovium (Fig. 1) and in a sclerodermatous skin lesion as well as in the fibrous capsule surrounding the implants in both patients (Fig. 2). The silastic envelope has been reported to be semipermeable with substances passing freely into and out of the implant. The polymer usually contains silica filler with a particle size of 30μm to impart added firmness, however, these sharp pointed crystals have not been fully characterized by Electron Microscopy. Silicone has been thought to be relatively inert, eliciting little or no tissue reaction. The substance has been injected or surgically placed into the human body as liquid, joints or in the form of breast augmentation prostheses. Recent reports have indicated that there is more than sufficient reason to change our thinking regarding this chemical and it's significance in biological reactions. There are 100,000 patients who undergo breast augmentation each year in the United States alone with over one million reported silicone implants. One clinical group reported that 4.4% of all new scleroderma patients had silicone breast implants. The patients reported in the study had implants from 2 to 21 years duration. The latency period may mean that scleroderma will increase parallel to the increase in breast augmentation over the last decade.


2021 ◽  
Vol 17 (2) ◽  
pp. 91-98
Author(s):  
Nadia Aladari ◽  
Mihaela Perțea ◽  
Camelia Tamas ◽  
Iulia Dabija Olaru ◽  
Madalina Palaghia ◽  
...  

Breast augmentation with silicone implants is one of the most common procedures performed by plastic surgeons around the world. Capsular contracture is one of the complication in breast augmentation that requires invasive reparation surgery. The inflammatory response to the breast implants appears to be directly associated with capsular contracture. In addition to the type of material (saline vs. silicone) used and it’s texture (smooth vs. textured), a number of factors were detected related to their position and the existence of a history of radiotherapy after cancer treatment for breast cancer. It tries to identify ideal methods to prevent and minimize the risk of developing capsular contracture. Among the methods currently used were described: placement of the implant in the retropectoral plane, dissection of a larger pocket, performing a rigorous hemostasis, use of implants with textured surface, minimizing the exposure time, contact and handling of the implant, irrigation of the pocket with antiseptic solutions (5% betadine) or broad-spectrum antibiotic solution to prevent the infectious process, the use of talc-free gloves, the use of corticosteroids, immuno-modulators and anti-inflammatory drugs.


2019 ◽  
Vol 70 (5) ◽  
pp. 1619-1624
Author(s):  
Silviu Adrian Marinescu ◽  
Dan Mircea Enescu ◽  
Catalin Gheorghe Bejinariu ◽  
Carmen Giuglea

The upward trend of patients opting for elective breast augmentation, as well as the large number of patients benefiting from alloplastic breast reconstruction, require further studies on the safety profile of these techniques. Without any doubt, the incidence of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) has drawn attention to the possible unknown complications characteristic of these procedures, creating the context of further studies devoted to this issue. The present research examines the capsular contracture rate on a group of 253 patients between 2015 and 2019, also proposing a scoring system based on the integration of the main diagnostic criteria related to the capsular contracture. The results of the literature review indicate that a lower incidence of capsular contracture could be achieved by using the newest techniques in the field involving the application of chemical substances on the surface of the latest generation of silicone breast implants.


Sign in / Sign up

Export Citation Format

Share Document